Cargando…

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

AIMS: To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide (IDegLira) with that used in previous DUAL trials in insulin‐naïve patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This 32‐week, open‐label, non‐inferiority trial randomized adults...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Stewart B., Kocsis, Győző, Prager, Rudolf, Ridge, Terry, Chandarana, Keval, Halladin, Natalie, Jabbour, Serge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484356/ https://www.ncbi.nlm.nih.gov/pubmed/28124817 http://dx.doi.org/10.1111/dom.12892

Ejemplares similares

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
por: Watada, Hirotaka, et al.
Publicado: (2019)

Physicians’ real-world experience with IDegLira: results of a European survey
por: Drummond, Russell, et al.
Publicado: (2018)

Correction: Physicians’ real-world experience with IDegLira: results of a European survey
Publicado: (2018)

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
por: Eliasson, Björn, et al.
Publicado: (2020)

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
por: Ericsson, Åsa, et al.
Publicado: (2017)

Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM
por: Kawaguchi, Yuji, et al.
Publicado: (2022)

IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin
por: Bostandzic, Amela Dizdarevic, et al.
Publicado: (2022)

One‐year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes
por: Taybani, Zoltán J., et al.
Publicado: (2022)

Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
por: Pöhlmann, Johannes, et al.
Publicado: (2019)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2017)

Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations
por: Builes-Montaño, C., et al.
Publicado: (2023)

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
por: Garnica-Cuellar, Juan Carlos, et al.
Publicado: (2023)

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)
por: Morales, Javier, et al.
Publicado: (2015)

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
por: Freemantle, Nick, et al.
Publicado: (2015)

Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
por: Kvapil, Milan, et al.
Publicado: (2017)

IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
por: Hunt, Barnaby, et al.
Publicado: (2017)

DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs
por: Wang, Weiqing, et al.
Publicado: (2022)

Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system
por: Psota, Marek, et al.
Publicado: (2017)

Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice
por: Egede, Leonard E., et al.
Publicado: (2020)

Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
por: Holst, Jens J., et al.
Publicado: (2015)

Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center
por: Sofra, Daniela
Publicado: (2017)

Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
por: Ramírez-Rincón, Alex, et al.
Publicado: (2022)

How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
por: Tibaldi, Joseph, et al.
Publicado: (2020)

Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study
por: Szépkúti, Sándor, et al.
Publicado: (2022)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy
por: Miller, Eden, et al.
Publicado: (2019)

Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study
por: Tramunt, Blandine, et al.
Publicado: (2022)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r5bhk8rnul8am406uobfehn9i5